1491026-40-4

Upstream product

• 130606-67-6 C₁₁H₁₈O₄ 
• 93635-76-8 (2S,3R)-3-[(4R)-2,2-dimethyl-[1,3]dioxolane-4-yl]-2,3-dihydroxy-2-methylpropionic acid ethyl ester 
• 879551-01-6 (4S,5R)-ethyl-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-meth-yl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide 
• 1020063-91-5 C₁₁H₁₈O₇S 
• 1491026-38-0 C₇H₉NO₄ 
• 98-88-4 benzoyl chloride 
• 1491026-36-8 C₁₂H₁₈NO₈S^(1-)*C₁₆H₃₆N⁽¹⁺⁾ 

Downstream Products

• 1597415-93-4 C₂₇H₂₃N₅O₅ 
• 1597416-03-9 C₃₃H₄₈N₄O₅SSi₂ 
• 1491026-43-7 C₂₁H₁₉NO₆ 
• 1491026-45-9 C₃₃H₂₈NO₉P 
• 1491026-79-9 C₃₃H₂₈NO₉P 

Relevant academic research and scientific papers

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2′-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Cyano Substituted Nucleoside Derivative, and methods of using the 2′-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Compounds of Formula (I) are disclosed, wherein R1, R2, R3, R4, R5, and R18 are defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.